EN DE
Watch Nanologica AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nanologica AB (NICA) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Nanologica AB stock SEK 0.09, price SEK 0.17, upside -48.5%, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0005454873

NA Nanologica AB logo Thin data Oct 31, 2026

Nanologica AB

NICA · ST
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Solidly profitable · 14.5% net margin (TTM)
Low debt
Ranks above peers (7/11)
Costs just 0.5 times its yearly profit.
Expensive Growth (revenue 5y +5.5 %/yr in SEK)
Fair value kr 0.0850 · Strongly overvalued (−48.5%)
Quality 25/100
Negative free cash flow
Narrow moat 33/100 · thin data
Thin data
⚠ Dilution
Watch Nanologica AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 16.35 kr 0.1620 Fair Value kr 0.0850 Aug 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 31, 2026.

How to read this chart

60‑month range kr 0.1620 – kr 16.35 · the kr 0.1650 price screens above the kr 0.0850 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 31, 2026.

Follow Nanologica in your weekly email

Every Wednesday you see whether Nanologica is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally.

Show moreShow less

The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purification by preparative chromatography used for products outside the peptide range.

It also provides high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces; and analytical chromatography, an analysis method in the pharmaceutical and food industries.

The company's products are used to purify substances with a focus on peptide drugs for the treatment of diabetes and obesity.

It serves pharmaceutical companies, as well as contract manufactures of insulin and insulin analogues, GLP-1 analogues, biosimilars to insulin and GLP-1 analogues, and other peptide drugs. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.

Stock analysis

Nanologica AB (NICA) currently trades at kr 0.1650, while our model-based Fair Value estimate is kr 0.0850, 48.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nanologica AB reported revenue of 21.1M SEK in FY2025 versus 12.9M SEK in FY2021, a compound +13.1%/yr. Reported net income was −51.3M SEK in FY2025.

Key figures

Market cap 54.2M SEK (≈ $5.5M) Micro · P/E ratio 0.5 · P/S ratio 0.42 · EPS (TTM) kr 0.3500 · Return on equity 18.1% · Return on assets (EBIT) −51.4% · Operating margin −79.8% · Revenue growth (YoY) +931%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −48%, NICA screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.2915 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) n/a kr 0.0100 kr 0.0100 52
All 1 models by family
Asset-Based
NCAV (Graham) n/a kr 0.0100 kr 0.0100 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 25
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 48/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+45.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+138.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +20.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−124.6% (2020) → −222.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NICA screens overvalued: fair value 48% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nanologica AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −48.5% · Below median
Profitability
Return on equity (12 months) 18.1% · Top 25%
Return on assets −58.2% · Bottom 25%
Net margin (12 months) 14.5% · Above median
Operating margin (12 months) −79.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 931.1% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 0.5× · Cheapest 25%
P/B 0.24× · Cheapest 25%
P/S (12 months) 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)72 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $116.80 $203.62 +74% vs NICA
Regeneron Pharmaceuticals, Inc REGN $818.77 $1,275 +56% vs NICA
Vertex Pharmaceuticals Incorporated VRTX $540.00 $594.00 +10% vs NICA
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs NICA
WuXi Biologics (Cayman) Inc 2269 HK$45.06 HK$49.57 +10% vs NICA
argenx SE ARGX $882.48 $908.40 +3% vs NICA
CSL Limited CSL A$200.73 A$178.58 −11% vs NICA
BeOne Medicines AG 6160 HK$217.60 HK$153.56 −29% vs NICA
Celltrion, Inc 068270 189,300 KRW 74,945 KRW −60% vs NICA
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs NICA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanologica AB · Fair Value
kr 0.0850 −48%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nanologica AB Fair Value". https://www.fairvalue-calculator.com/stock/NICA

Frequently asked questions

Is Nanologica AB (NICA) overvalued or undervalued?
As of Oct 31, 2026, our model estimates a fair value of kr 0.0850 versus a price of kr 0.1650, about −48% upside (overvalued).
What is the fair value of NICA?
Our model-based fair value for Nanologica AB is kr 0.0850 (as of Oct 31, 2026), built from audited fundamentals. The current price: kr 0.1650.
What is the quality score of NICA?
Nanologica AB has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanologica AB (NICA)?
Our model-based price target is the fair value of kr 0.0850 (as of Oct 31, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanologica AB stock forecast for 2026?
Our models put fair value at kr 0.0850, about −48% upside versus a price of kr 0.1650 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Nanologica AB (NICA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanologica AB it is kr 0.0850 per share (as of Oct 31, 2026), against a price of kr 0.1650. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Nanologica AB stock overvalued or undervalued in 2026?
As of Oct 31, 2026, NICA trades above its calculated fair value: price kr 0.1650, fair value kr 0.0850, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NICA?
No. The price is what the market pays today (kr 0.1650); the fair value is what the company's own numbers justify (kr 0.0850). For Nanologica AB the two are kr 0.0800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanologica AB worth?
The market values Nanologica AB at about 54.2M SEK (market capitalisation, as of Oct 31, 2026). Per share that is kr 0.1650; our models calculate a fair value of kr 0.0850 per share.
What is the P/E ratio of NICA?
Nanologica AB trades at a price-to-earnings ratio of 0.5 (as of Oct 31, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 0.0850 is built from several models across several years. Other multiples: P/B 0.2, P/S 0.0.
How solid is the balance sheet of Nanologica AB (NICA)?
Balance-sheet figures for Nanologica AB (as of Oct 31, 2026): return on equity 18.1%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is NICA from its 52-week high?
Nanologica AB trades at kr 0.1650, about 90% below its 52-week high of kr 1.68 and 2% above the low of kr 0.1620 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0850 is for.
Which stocks are comparable to Nanologica AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanologica AB stock attractive at the current price?
The data as of Oct 31, 2026: price kr 0.1650, calculated fair value kr 0.0850 (−48%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NICA calculated?
We run Nanologica AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0850, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Nanologica AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanologica AB (NICA)?
The closing price on Oct 30, 2026 was kr 0.1650. Our model-based fair value is kr 0.0850, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanologica AB right now?
Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Nanologica AB

How large is the market capitalisation of Nanologica AB (NICA)?
The market capitalisation of Nanologica AB is 54.2M SEK (≈ $5.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanologica AB (NICA)?
The price-to-sales ratio of Nanologica AB is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanologica AB (NICA)?
Earnings per share at Nanologica AB are kr 0.3500 (price ÷ EPS = P/E 0.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nanologica AB (NICA)?
The return on equity (ROE) of Nanologica AB is 18.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanologica AB (NICA)?
On an EBIT basis the return on assets of Nanologica AB is −51.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanologica AB (NICA)?
The operating margin of Nanologica AB is −79.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanologica AB (NICA)?
Revenue at Nanologica AB is growing +931% versus a year earlier (3y avg +139%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nanologica AB (NICA) generate?
The free cash flow of Nanologica AB is −40.9M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nanologica AB (NICA) carry?
The net debt of Nanologica AB is 17.9M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nanologica AB in the live analysis

One click puts Nanologica AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.